Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06039384 |
TitleA Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation | Phase
Phase 1
|
Date Added 2023-09-15 |
Location
California, United States
Colorado, United States Michigan, United States Texas, United States Virginia, United States Italy Spain United Kingdom |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Adagrasib, INCB099280 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05652894 |
TitleA Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer | Phase
Phase 3
|
Date Added 2022-12-15 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
HX008, Investigator's Choice Chemotherapy |
Tags
MSI-H/ MMRd
|
| NCT ID NCT03970382 |
TitleA Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Phase
Phase 1
|
Date Added 2019-05-31 |
Location
California, United States
Illinois, United States New York, United States Tennessee, United States Washington, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Suspended
|
Drugs
IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03013218 |
TitleA Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | Phase
Phase 1
|
Date Added 2017-01-06 |
Location
Colorado, United States
Connecticut, United States Massachusetts, United States Michigan, United States Washington, United States Korea, Republic of |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
5-FU + Cisplatin, Evorpacept (ALX148), Pembrolizumab, Ramucirumab + Paclitaxel, Rituximab, Trastuzumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04607421 |
TitleA Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER) | Phase
Phase 3
|
Date Added 2020-10-29 |
Location
Arizona, United States
California, United States Florida, United States Illinois, United States Louisiana, United States Minnesota, United States Missouri, United States Nebraska, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany India Italy Japan Korea, Republic of Mexico Netherlands New Zealand Norway Poland Russian Federation Slovakia South Africa Spain Sweden Taiwan Ukraine United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT05217446 |
TitleA Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK ) | Phase
Phase 2
|
Date Added 2022-02-01 |
Location
Arizona, United States
California, United States Florida, United States Illinois, United States Minnesota, United States New York, United States Tennessee, United States Texas, United States Australia Belgium Canada Czechia Denmark France Germany Italy Netherlands Norway Poland Slovakia Spain Sweden United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
encorafenib, Braftovi, Erbitux, Keytruda |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05726864 |
TitleA Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2023-02-14 |
Location
Arizona, United States
California, United States Colorado, United States Florida, United States Georgia, United States Iowa, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
ELI-002 7P |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04104776 |
TitleA Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas | Phase
Phase 1
|
Date Added 2019-09-26 |
Location
Georgia, United States
Illinois, United States Maryland, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States Washington, United States France Italy Korea, Republic of Poland Spain United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
CPI-0209, CPI-0209 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05759728 |
TitleA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2023-03-08 |
Location
Australia
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03783403 |
TitleA Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers | Phase
Phase 1
|
Date Added 2018-12-21 |
Location
Alabama, United States
Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada France Italy Korea, Republic of Spain United Kingdom |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
CC-95251, cetuximab, Rituximab |
Tags
MSS/ MMRp
|
